LLY

987.98

+2.24%↑

JNJ

224.37

+1.35%↑

ABBV

207.85

+2.48%↑

UNH

396.24

+3.1%↑

AZN

184.48

+1.46%↑

LLY

987.98

+2.24%↑

JNJ

224.37

+1.35%↑

ABBV

207.85

+2.48%↑

UNH

396.24

+3.1%↑

AZN

184.48

+1.46%↑

LLY

987.98

+2.24%↑

JNJ

224.37

+1.35%↑

ABBV

207.85

+2.48%↑

UNH

396.24

+3.1%↑

AZN

184.48

+1.46%↑

LLY

987.98

+2.24%↑

JNJ

224.37

+1.35%↑

ABBV

207.85

+2.48%↑

UNH

396.24

+3.1%↑

AZN

184.48

+1.46%↑

LLY

987.98

+2.24%↑

JNJ

224.37

+1.35%↑

ABBV

207.85

+2.48%↑

UNH

396.24

+3.1%↑

AZN

184.48

+1.46%↑

Начало・Списък с акции・OraSure Technologies Inc

OraSure Technologies Inc

Затворен

СекторЗдравеопазване

2.96 -1.66

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

2.86

Максимум

3.05

Ключови измерители
By Trading Economics
Приходи	-6.3M -22M
Продажби	1.2M 28M
EPS	-0.24
Марж на печалбата	-80.132
Служители	500
EBITDA	-1.8M -21M

Дивиденти
By Dow Jones
Следващи печалби	4.08.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-4.4M 208M
Предишно отваряне	4.62
Предишно затваряне	2.96

Настроения в новините

By Acuity

80%

20%

18 / 346 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Strong Bearish Evidence

N/A / 2.975 Подкрепа & съпротива

OraSure Technologies Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

12.05.2026 г., 22:50 ч. UTC

Печалби

Commonwealth Bank of Australia Increases Provisions as 3Q Profit Slips

12.05.2026 г., 22:49 ч. UTC

Печалби

Aristocrat Leisure Raises Midyear Dividend, Swells Share Buyback Program

12.05.2026 г., 22:32 ч. UTC

Печалби

JBS 1Q Profit Slides Amid Rising Cattle Costs -- Update

12.05.2026 г., 23:48 ч. UTC

Пазарно говорене

Nikkei May Decline Amid Uncertainty Over Iran Conflict -- Market Talk

12.05.2026 г., 22:57 ч. UTC

Пазарно говорене

Печалби

JBS Says Consumers Are Looking to Pork for Affordable Protein -- Market Talk

12.05.2026 г., 22:26 ч. UTC

Печалби

Aristocrat Leisure to Increase On-Market Share Buyback by A$1 Billion

12.05.2026 г., 22:25 ч. UTC

Печалби

Aristocrat Leisure 1H Normalized Pretax Profit A$997.3 Million, Up 9.4% on Year

12.05.2026 г., 22:25 ч. UTC

Печалби

Aristocrat Leisure Interim Dividend A$0.50/Security

12.05.2026 г., 22:24 ч. UTC

Печалби

Aristocrat Leisure 1H Revenue From Continuing Operations A$3.03 Billion, Down 0.2% on Year

12.05.2026 г., 22:23 ч. UTC

Печалби

Aristocrat Leisure 1H Net Profit From Discontinued Operations A$7.0 Million

12.05.2026 г., 22:23 ч. UTC

Печалби

Aristocrat Leisure 1H Net Profit From Continuing Operations A$798.5 Million, Up 56%

12.05.2026 г., 22:19 ч. UTC

Печалби

CBA: Total Provision Coverage Ratio 1.57%>CBA.AU

12.05.2026 г., 22:14 ч. UTC

Печалби

CBA: Business Lending Continued to Grow Above System>CBA.AU

12.05.2026 г., 22:14 ч. UTC

Печалби

CBA Had 1.4M Business Transaction Accounts at March 31, Up 7% on Year>CBA.AU

12.05.2026 г., 22:13 ч. UTC

Печалби

CBA Household Deposits Grew A$38B in 12 Months Through March>CBA.AU

12.05.2026 г., 22:12 ч. UTC

Печалби

CBA Home Loan Balances Grew A$41B in 12 Months Through March>CBA.AU

12.05.2026 г., 22:12 ч. UTC

Печалби

CBA 3Q New Home Loan Funding A$45B>CBA.AU

12.05.2026 г., 22:11 ч. UTC

Печалби

Correct: JBS NV 1Q EPS 20c, Not 21c >JBS

12.05.2026 г., 22:11 ч. UTC

Печалби

CBA: CET1 Level 2 Capital Ratio 11.6%>CBA.AU

12.05.2026 г., 22:10 ч. UTC

Печалби

CBA: Customer Deposit Funding Ratio 79%>CBA.AU

12.05.2026 г., 22:09 ч. UTC

Печалби

CBA: Underlying Portfolio Credit Quality Remains Sound>CBA.AU

12.05.2026 г., 22:09 ч. UTC

Печалби

CBA: Higher Collective Provisions Reflect Geopolitical, Macroeconomic Uncertainty >CBA.AU

12.05.2026 г., 22:08 ч. UTC

Печалби

CBA 3Q Loan Impairment Expense A$316M>CBA.AU

12.05.2026 г., 22:07 ч. UTC

Печалби

CBA: Costs Up on Higher Cloud Computing Volumes, Software Licenses, AI Investment>CBA.AU

12.05.2026 г., 22:06 ч. UTC

Печалби

CBA 3Q Operating Expenses Up 1% Excluding Restructuring, Notable Items>CBA.AU

12.05.2026 г., 22:06 ч. UTC

Печалби

CBA: 3Q Underlying Net Interest Margin Was Broadly Stable>CBA.AU

12.05.2026 г., 22:05 ч. UTC

Печалби

CBA: Lending, Deposit Volume Growth Offset Impact of Two Fewer Days >CBA.AU

12.05.2026 г., 22:04 ч. UTC

Печалби

Commonwealth Bank: Operating Income Flat in March Quarter >CBA.AU

12.05.2026 г., 22:04 ч. UTC

Печалби

Commonwealth Bank 3Q Cash Profit Up 4% on Year>CBA.AU

12.05.2026 г., 22:04 ч. UTC

Печалби

Commonwealth Bank 3Q Cash Profit Down 1% on 1H Quarterly Average>CBA.AU

Сравнение с други в отрасъла

Ценова промяна

OraSure Technologies Inc Прогноза

Консенсусна оценка

By TipRanks

0 ratings

Купи

Задържане

Продай

Според 0 анализатори, дали борсови рейтинги на OraSure Technologies Inc през последните 3 месеца.

Техническа оценка

By Trading Central

N/A / 2.975Подкрепа & съпротива

Recent bearish events outweigh bullish events.

Bearish events outweigh bullish events.

There are no events.

Настроение

By Acuity

18 / 346 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно OraSure Technologies Inc

OraSure Technologies, Inc., together with its subsidiaries, provides point-of-care and home diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services in the United States, Europe, and internationally. The company's products include InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebola rapid antigen test, OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D. saliva alcohol test. It also offers genomic products under the Oragene and ORAcollect brands for collecting genetic material from human saliva; Colli-Pee collection devices for the volumetric collection of void urine samples; and microbiome laboratory testing and analytical services. In addition, the company provides microbiome products, such as OMNIgene GUT for self-collecting microbial DNA from feces or stool samples for gut microbiome profiling; OMNIgene GUT DNA and RNA collection devices; and OMNIgene GUT Dx collection device for collection of human fecal samples and the stabilization of DNA from the bacterial community. Additionally, it provides other diagnostic products, such as immunoassays and other in vitro diagnostic tests. The company markets its products to clinical laboratories, hospitals, clinics, community-based organizations and other public health organizations, distributors, government agencies, physicians' offices, commercial and industrial entities, disease risk management, diagnostics, pharmaceutical, biotech, nutrition, companion animal, and environmental markets. OraSure Technologies, Inc. was incorporated in 2000 and is based in Bethlehem, Pennsylvania.